Answers are grounded in this paper and cite their sources.
Efflux transporters such as P-glycoprotein play an important role in drug transport in many organs. In the gut, P-glycoprotein pumps drugs back into the lumen, decreasing their absorption. Drugs which induce P-glycoprotein, such as rifampicin, can reduce the bioavailability of some other drugs. Inhibitors of P-glycoprotein, such as verapamil, increase the bioavailability of susceptible drugs. Many, but not all, of the drugs which are transported by P-glycoprotein are also metabolised by cytochrome P450 3A4. Important substrates of P-glycoprotein include calcium channel blockers, cyclosporin, dabigatran etexilate, digoxin, erythromycin, loperamide, protease inhibitors and tacrolimus. Predicting clinically important interactions is difficult because of interindividual differences in drug transport.
No takes yet. Share an insight, caveat, or question.
Finch et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: